Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMI 9523

Next Previous
Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523; LMWF 5A

Latest Information Update: 24 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ampio Pharmaceuticals
  • Developer Ampio Pharmaceuticals; Vanderbilt University
  • Class Antirheumatics; Dipeptides; Eye disorder therapies; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; COVID 2019 infections; Crohn's disease; Eye disorders; Inflammation; Neurological disorders; Osteoarthritis; Post acute COVID 19 syndrome; Protein-losing enteropathy; Rhinitis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 21 Apr 2023 Ampion Pharmaceuticals has discontinues certain patents covering Ampion®
  • 10 Feb 2023 Discontinued - Phase-I for Post-acute-COVID-19-syndrome in USA (Inhalation)
  • 10 Feb 2023 Discontinued - Phase-II for SARS-COV-2 acute respiratory disease in India, USA (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top